Twist mediates an aggressive phenotype in human colorectal cancer cells

  • Authors:
    • Jun-Jian Deng
    • Wei Zhang
    • Xi-Ming Xu
    • Fan Zhang
    • Wei-Ping Tao
    • Jun-Jie Ye
    • Wei Ge
  • View Affiliations

  • Published online on: January 15, 2016     https://doi.org/10.3892/ijo.2016.3342
  • Pages: 1117-1124
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epithelial-mesenchymal transition (EMT) is a crucial process providing cancer cells with the ability to migrate and metastasize to distant sites. Recently, EMT was shown to be associated with the cancer stem cell (CSC) phenotype and chemoresistance. Twist is a transcription factor that regulates EMT in a various cancer cells, including colorectal cancer (CRC). Our study was done to determine the role of Twist in mediating aggressive phenotype in CRC. Human CRC cell lines were transduced with a retroviral Twist construct or vector control. Migration and invasion abilities were determined in vitro using modified Boyden chamber assays. Mammosphere formation assay was performed to detect CSC characteristics. EMT and CSC markers were detected using western blotting and RT-PCR. Chemosensitivity to oxaliplatin of the transfected cells were determined by the MTT assay. Human CRC specimens were stained for Twist and P-gp expression. Twist overexpression triggered EMT and a CSC-like phenotype in human CRC cells and enhanced cell migration, invasion and mammosphere formation abilities. In addition, Twist-overexpressing CRC cells were more chemo­resistant to oxaliplatin than control cells. Furthermore, Twist over­expression increased P-gp expression in CRC cells, which is a transmembrane glycoprotein conferred multidrug-resistance phenotype to various cancer cells. Importantly, Twist and P-gp were expressed correlatively in human CRC specimens. Thus, Twist is a potential therapeutic target in metastatic CRC.

Introduction

Epithelial-mesenchymal transition (EMT), a crucial phenotypic conversion during embryonic development, wound healing and tissue remodeling, plays an essential role in tumor invasion and metastasis (13). As a reversible process, EMT often occurs at the invasive front of many metastatic cancers (4). Different signals received from tumor microenvironment can trigger EMT conversion, such as TGFβ, TNFα, EGF and Notch (5,6). During EMT conversion, epithelial cells lose intercellular adhesion, acquire mesenchymal characteristics and increase migratory and invasive capabilities (7). The hallmark of EMT is loss of E-cadherin expression (1). A set of transcription factors have been implicated in the regulation of EMT, including Twist, Snail, Slug and ZEB1 (8). Twist, a member of zinc-finger transcription factor, has been proved as a central EMT regulator. Studies showed that Twist induces EMT by binding to the E-box site in the promoter of E-cadherin and repressing E-cadherin transcription (9). Twist plays an important role in the pathogenesis of various malignant tumors, predominantly by promoting invasiveness and metastatic behavior. Twist is overexpressed in a variety of cancers, including breast cancer, hepatocellular carcinoma, prostate cancer, head and neck squamous cell carcinoma and ovarian cancer (9). In breast cancer and lung cancer, Twist expression is associated with a more aggressive phenotype and poorer clinical outcome (10). Furthermore, several studies revealed a correlation between Twist expression and metastatic disease. Twist expression levels were positively correlated with high grade and metastasis of prostate cancer and bladder cancer (11,12).

Recently, increasing studies suggested that EMT phenotype also led to the acquisition of other properties involved in tumor progression, such as increased resistance to chemotherapy drug and acquisition of cancer stem cell (CSC)-like features (13). The CSCs are a group of cells within a tumor that possess the capacity to self-renew and differentiate into the heterogeneous lineages of cancer cells which compose the whole tumor (14). Mounting studies showed that somatic cells can be reprogramed into pluripotent stem-like cells via co-expression of pluripotent makers such as Bmi-1, Nanog and CD44 (15). A recent study confirmed that drug-resistant lung cancer cells display a cancer stem-like trait and EMT phenotype (16). Taken together, these observations suggested that EMT and CSC-like properties are mechanistically associated to chemoresistance.

Colorectal cancer (CRC) is a major worldwide health concern. Most deaths from CRC are due to metastases that are resistant to conventional therapies. Analysis of Twist in CRC specimens in a recent study suggested that Twist can be an important marker of poor prognosis (17). However, the specific role of Twist in aggressive phenotype of CRC is has not been fully elucidated. In this study we showed that upregulation of Twist confers aggressive phenotype of CRC cells by inducing EMT and CSC properties. Moreover, we demonstrated that high levels of Twist expression in CRC cells are linked to increased chemoresistance.

Materials and methods

Chemicals and reagents

Primary antibody against E-cadherin was obtained from Cell Signaling Technology (Danvers, MA, USA). Primary antibodies against N-cadherin, vimentin, Twist, P-gp and α-tubulin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies against Bmi-1 and Nanog were obtained from Epitomics. Alexa Fluor 488/594 conjugated secondary antibody, Horseradish peroxidase (HRP)-conjugated secondary antibody, DAPI and Lipofectamine 2000 were from Invitrogen (Carlsbad, CA, USA). PrimeScript® RT reagent kit and SYBR® Premix Ex Taq™ were from Takara. E.Z.N.A® HP Total RNA kit was obtained from Omega Bio-Tek (Doraville, GA, USA).

Cell culture

The colorectal carcinoma cell lines HCT116 and SW480 were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). SW480 cells were cultured in DMEM culture medium (Gibco BRL) supplemented with 10% fetal bovine serum, and HCT116 cells were maintained in McCoy'5a culture medium (Gibco BRL) supplemented with 10% fetal bovine serum under a humidified 5% CO2 atmosphere at 37°C in an incubator.

Transwell migration and invasion assay

Invasion and migration assays were performed in Boyden chambers. The polycarbonate filters, pre-coated with Matrigel matrix, were used for invasion assay, and uncoated filters were used for migration assay. Cells (1×105) in 300 μl medium (containing 0.1% FBS) transfected with empty vector plasmid or pcDNA-Twist were seeded in the upper chamber. Then 600 ml medium with 10% FBS, served as a chemotactic agent, and was added to the lower chamber. For migration, after 24 h incubation, the cells migrated onto the lower chamber were fixed with 4% paraformaldehyde for 30 min, stained with hematoxylin and counted under microscope. For invasion, the cells in the upper chamber were fixed in 4% paraformaldehyde for 30 min. Then the Matrigel was removed from the filter with a cotton swab. The cells adhered to the underside of the filter were stained with hematoxylin and counted under a microscope. Each assay was repeated in three independent experiments.

Gene overexpression

Cells/well (2×105) were seeded on a 6-well plate and left in culture until the next day. They were then transfected with 2 μg empty vector plasmid or pcDNA-Twist mixed with Lipofectamine 2000 reagent in serum-free medium according to the manufacturer's instructions. After 6 h, medium was changed to complete culture medium and the cells were incubated for another 24–48 h before harvest.

Quantitative real-time PCR

Total mRNA of the cells was extracted after transfected with plasmids for 24 h. First step cDNA synthesis was generated from 500 ng total mRNA. Quantification of target and reference genes were detected in triplicate on LightCycler® 480 II. The primers used in each reaction are shown in Table I. Expression levels for each target gene were normalized to GAPDH gene. Results were calculated using the comparative threshold cycle (ΔΔCT) method. Data are presented as the mean ± standard deviation (SD) from three independent experiments.

Table I

Primers used in this study.

Table I

Primers used in this study.

GeneForward primer 5′-3′Reverse primer 5′-3′
Twist GGAGTCCGCAGTCTTACGAG TCTGGAGGACCTGGTAGAGG
E-cadherin TACACTGCCCAGGAGCCAGA TGGCACCAGTGTCCGGATTA
Vimentin TGAGTACCGGAGACAGGTGCAG TAGCAGCTTCAACGGCAAAGTTC
Bmi-1 TGGAGAAGGAATGGTCCACTTC GTGAGGAAACTGTGGATGAGGA
Nanog CAAAGGCAAACAACCCACTT TCTGCTGGAGGCTGAGGTAT
CD44 GACACATATTGTTTCAATGCTTCAGC GATGCCAAGATGATCAGCCATTCTGGAAT
ABCB1 TGCTCAGACAGGATGTGAGTTG AATTACAGCAAGCCTGGAACC
ABCC1 GCCAAGAAGGAGGAGACC AGGAAGATGCTGAGGAAGG
ABCC2 TGGTGGCAACCTGAGCATAGG ACTCGTTTTGGATGGTCGTCTG
ABCC3 CTTAAGACTTCCCCTCAACATGC GGTCAAGTTCCTCTTGGCTC
ABCG2 TATAGCTCAGATCATTGTCACAGTC GTTGGTCGTCAGGAAGAAGAG
ABCC4 GGTTCCCCTTGGAATCATTT AATCCTGGTGTGCATCAAACAG
ABCC5 ACCCGTTGTTGCCATCTTAG GCTTTGACCCAGGCATACAT
ERCC1 CTCAAGGAGCTGGCTAAGATGT CATAGGCCTTGTAGGTCTCCAG
XRCC1 CATCGTGCGTAAGGAGTGGGTG AGTGGGCTTGGTTTTGGTCTGG
MSH2 GCTTCTCCTGGCAATCTCTCTC TACCCAACTCCAACCTGTCTCT
TUBB3 TCAGCAAGGTGCGTGAGGAGTAT CGGAAGCAGATGTCGTAGAGCG
POLH CGTGGGAGCAGTGATTGTGGAGGA GGTTTGGCGGTTGGGCTTGTTTAG
GSTπ ACCTCCGCTGCAAATACATC CTCAAAAGGCTTCAGTTGCC
γGT1 GCCTGGATTCTCCCAGAGAT GGAGAGCACCTCTTCCTCAG
GAPDH GCACCGTCAAGGCTGAGAAC TGGTGAAGACGCCAGTGGA
Western blot analysis

The cells were washed three times with ice-cold PBS and then lysed in lysis buffer. Lysates were cleared by centrifugation and denatured by boiling for 5 min in Laemmli buffer. Equal quantity of protein samples were loaded per well and separated on SDS-polyacrylamide gels, and then transferred electrophoretically onto PVDF membranes. After blocked with 5% non-fat milk at room temperature for 2 h, membranes were incubated with primary antibodies at 4°C overnight and then incubated with HRP-conjugated secondary antibodies for 1.5 h at room temperature. Immune complexes were detected using Western Blotting Plus chemiluminescence reagent.

Immunofluorescence

The cells transfected with plasmids were cultured on chamber slides for 24 h, then washed three times with PBS, fixed with 4% paraformaldehyde for 30 min and permeabilized with 0.3% Triton X-100 for 10 min. After blocked with goat serum for 2 h at room temperature, cells were incubated with antibodies against E-cadherin, vimentin (1:100 dilution) at 4°C overnight. Slides were washed three times with PBS and incubated with Alexa Fluor 488 or Alexa Fluor 594-conjugated secondary antibodies (1:1,000 dilution) for 1 h at room temperature. Nuclei were stained with DAPI (10 μg/ml) for 10 min. Samples were examined with Confocal Laser Scanning Microscopy (Zeiss) to analyze expression of E-cadherin, vimentin.

Mammosphere formation assay

Stem cells are enriched in mammospheres of cancer cells and assay is based on the ability of stem cells to grow and form spheres in serum-free medium. Mammosphere culture was done in a serum-free DMEM/F12 supplemented with 20 ng/ml EGF, B27, 20 ng/ml basic fibroblast growth factor (bFGF), 1 g/ml hydrocortisone, 5 g/ml insulin and 1% antibiotic-antimycotic. Single cells prepared from mechanical dissociation were plated in 12-well ultralow attachment plates at a density of 1,000 cells/ml in culture. Single cell status was confirmed under a microscope. Fresh mammosphere culture was added every 3–4 days. After 7 days of culture, the number of mammospheres (>20 μm) was counted under an upright microscope and the images were acquired with the upright microscope. Each assay was carried out in triplicate and repeated in three independent experiments.

Cell viability assay

Cell viability was performed using the MTT assay. Briefly, cells (1×104) transfected with plasmids were seeded into each well of a 96-well plate and treated with oxaliplatin at concentrations from 5 to 20 μM for 24 h. After treatment, the cells were washed twice with PBS, and 100 ml of 0.25 mg/ml MTT inculture medium was added to each well. The plate was incubated at 37°C for 4 h. Then, the culture medium was removed, and 100 ml DMSO was added to each well to dissolve the dark blue crystal. The absorbance was measured at 570 nm using a microplate reader.

Immunohistochemistry

Sections cut from the human colorectal tumor paraffin blocks were subjected to deparaffinization/rehydration, and antigen retrieval by boiling in 0.01 M sodium citrate buffer for 30 min. The sections were blocked with 10% goat serum, then incubated with the primary antibodies against Twist and P-gp at a dilution 1:200 at 4°C overnight in a humidified chamber. After washing with PBS three times, slides were incubated with HRP-conjugated antibody, and DAB was used as substrate. Mayer's hematoxylin was applied as a counter stain. Throughout the above analyses, controls were prepared by omitting the primary antibodies.

Statistical analysis

Results are expressed as mean ± SD of three independent experiments unless otherwise specified. Data were analyzed by two-tailed unpaired Student's t-test between any two groups. One-way ANOVA analysis of variance was used to assess the difference of means among groups. These analyses were performed using GraphPad Prism Software Version 5.0 (GraphPad Software Inc., La Jolla, CA, USA). A P-value of <0.05 was considered statistically significant.

Results

Overexpression of Twist promotes migration and invasion of CRC cells

Tumor cells with an aggressive phenotype acquire invasive and migratory capabilities, which will promote the dissemination of tumors cells to distant organs (1). The migratory and invasive capabilities of HCT116 and SW480 cells transfected with vector plasmid or pcDNA-Twist were measured by using Transwell migration and invasion assays. As shown in Fig. 1A and B, overexpression of Twist led to an obvious increase in cell migration and invasion. Compared with control, the number of migrated and invasive cells increased about 5-fold (migration) and 15-fold (invasion) after overexpression of Twist.

The increased migratory and invasive capabilities of tumor cells are reminiscent of the molecular events at EMT. The morphology of HCT116 and SW480 cells was observed after transfection with pcDNA-Twist, we found that overexpression of Twist resulted in a significant change in cell morphology, from cobblestone phenotype to spindle-like and fusiform features (Fig. 1C).

Overexpression of Twist induces EMT of CRC cells

During EMT, the epithelial maker E-cadhein is downregulated, whereas the mesenchymal markers vimentin and N-cadherin are upregulated (18). To confirm whether HCT116 and SW480 cells transfected with pcDNA-Twist truly acquire EMT features, western blotting was used to examine the expression of EMT makers. As shown in Fig. 2A, overexpression of Twist decreased E-cadherin expression, which is consistent with increased vimentin and N-cadherin. Similarly, real-time PCR analysis further confirmed the increasing expression of vimentin and N-cadherin, and the decreased expression of E-cadherin at mRNA levels (Fig. 2B). Furthermore, immunofluorescence analysis showed that overexpression of Twist downregulated E-cadherin and upregulated vimentin (Fig. 2C). Collectively, these observations suggested that HCT116 and SW480 cells had undergone EMT following overexpression of Twist.

Overexpression of Twist induces a CSC-like phenotype of CRC cells

To investigate whether cells with EMT phenotype could display CSC-like features, we detected mammosphere forming ability of HCT116 and SW480 cells transfected with pcDNA-Twist. We found that cells overexpressing Twist showed obviously enhanced ability to form mammosphere compared to control cells. As shown in Fig. 3A, overexpression of Twist increased the number of mammospheres about 3–7-fold of HCT116 and SW480 cells. To further investigate the genes maintaining and regulating the CSC properties, we performed western blotting and real-time PCR analysis. The results from western blotting showed that overexpression of Twist significantly increased pluripotent makers Nanog and Bmi-1 expression levels (Fig. 3B). Real-time PCR analysis also demonstrated that the mRNA expression levels of Nanog, Bmi-1 and CD44 are obviously enhanced in cells overexpressing Twist compared to control cells (Fig. 3C). These findings demonstrated that overexpression of Twist induces a CSC-like phenotype of CRC cells.

Overexpression of Twist mediates chemoresistance of CRC cells

Recent studies showed that EMT phenotype and CSC-like trait are closely related to chemoresistance of cancer cells (13). We next observed whether overexpression of Twist can affect sensitivity of HCT116 and SW480 cells to oxaliplatin. HCT116 and SW480 cells transfected with control vector plasmid or pcDNA-Twist were treated with different concentration of oxaliplatin and MTT assay was performed. The results showed that overexpression of Twist led to a distinct increase in cell viability compared with cells transfected with control vector (Fig. 4A). Underlying molecular mechanisms of chemoresistance are extremely complicated, involving ATP binding cassette (ABC) membrane transport proteins and DNA repair proteins (19). We overexpressed Twist and detected drug resistance-associated genes, including ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCG2, ERCC1, XRCC1, MSH2, TUBB3, POLH, GSTπ and γ-GT1. Noteworthy, overexpression of Twist distinctly increased the mRNA expression of ABCB1, but not the others (Fig. 4B). P-gp, a transmembrane glycoprotein characterized based on its ability to confer a multidrug-resistance phenotype to cancer cells is an ABCB1 encoded protein (20). Further, we demonstrated that overexpression of Twist also enhanced the expression of P-gp in HCT116 and SW480 cells (Fig. 4C). Taken together, these observations suggested that P-gp may be essential for drug resistant phenotype induced by Twist.

Clinical corelation of Twist and P-gp expression in human CRC specimens

To further extend our findings in vivo, we determined whether there is a correlation between the expression of Twist and P-gp in resected human colorectal cancer specimens. Immunohistochemical analyses of Twist and P-gp were performed for 46 examples of tumor samples from colorectal cancer patients. A representative immunohistochemistry result is shown in Fig. 5, Twist expression was on the cell nuclei, while P-gp expressed on the cell membrane. Of note, expression of P-gp occurred in 28 cases (60.8%) and expression of Twist occurred in 26 cases (56.5%), indicating that there was an obvious association between Twist and P-gp expression (P<0.01; Table II).

Table II

Immunohistochemical staining of Twist and P-gp was performed in 46 tumor samples from colorectal cancer patients.a

Table II

Immunohistochemical staining of Twist and P-gp was performed in 46 tumor samples from colorectal cancer patients.a

P-gp

PositiveNegativeTotalP-value
Twist
 Positive21526
 Negative71320<0.01
Total281846

a The positive and negative expression levels of Twist and P-gp were counted and analyzed. P<0.01.

Discussion

Metastasis involves many steps such as successful invasion, intravasation, survival in the circulation, extravasation and colonization by the cancer cells. Many cancer types depend on the process of EMT for successful completion of these steps (1). EMT is thought to be the first step of tumor invasion and metastasis (4). It has been reported that the expression profiles of EMT are associated with tumor grades and metastasis of breast carcinoma (21,22). EMT also plays a crucial role in the metastasis of colorectal cancer, which occurs at the invasive front of colon carcinoma concomitant with a selective loss of basement membrane (23). Twist, a zinc-finger transcription factor, has been considered as a critical regulator that promotes EMT and induces invasiveness as well as metastasis in various types of malignant tumors (24). In CRC tissues, Twist was highly expressed and the inverse correlation between Twist and E-cadherin was observed (25). In addition, aberrant Twist expression associated significantly with lymph node metastasis of CRC (25). Consistent with the above investigations, our studies demonstrated that overexpression of Twist in CRC cells led to decreased E-cadherin expression and increased vimentin and N-cadherin expression. Furthermore, acquisition of mesenchymal phenotype has been associated with enhanced invasive and metastatic behavior.

Recently, it was proposed that EMT not only enables cancer cells to disseminate but also to acquire the ability to self-renew by inducing a CSC trait (26). The CSCs represent a small subset of cells within a malignant tumor thought to be capable of initiating the tumor and of driving its growth and recurrence after treatment (14). The relationship between EMT and CSC has been the focus of recent research. Mani et al demonstrated that overexpression of EMT regulators Snail and Twist in immortalized human mammary epithelial cells (HMLEs) induced an EMT state and conferred to the cells an increased ability to form mammospheres, which is characteristic of CSCs (27). Comparably, McCoy et al proved that the homeobox transcription factor Six1 induced tumors that underwent EMT in mouse mammary gland epithelium by increasing the population of cells displaying CSC markers (28). Similarly, recent research showed that gene expression patterns of CSC-associated pathways were involved in EMT (29). In line with these studies, we found that Twist-induced EMT conferred a CSC-like phenotype in CRC cells. Overexpression of Twist in two CRC cell lines resulted in increased expression of the CSC markers Bmi-1, Nanog and CD44 as well as enhanced ability to form mammospheres.

Increasing evidence suggested that both EMT and CSC phenotype are associated with chemoresistance (13). Cancer cells undergoing EMT become resistant to chemotherapy, and cancer cells selected for chemoresistance acquire EMT phenotype (1,16,30,31). Induction of EMT was detected to promote the decreased efficacy of chemotherapy in colorectal, breast and ovarian cancers (30,32,33). It has been demonstrated that chemoresistance is due to the existence of CSC features, which remain after treatment and result in cancer relapse. In this study, we also showed that the CRC cells overexpressing Twist exhibited EMT and CSC properties as well as resistance to chemotherapy. The cancer cells resistant to conventional therapies was primary due to altered expression of ATP binding cassette (ABC) membrane transport proteins (34), overexpression of the DNA repair enzymes (35), activation of DNA damage checkpoint responses and inhibition of cell apoptosis (19,36).

We next investigated the underlying mechanism of chemoresistance induced by Twist overexpression and our results showed that Twist significantly enhance ABCB1 mRNA level, but not the other drug resistance genes, such as ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCG2, ERCC1, XRCC1, MSH2, TUBB3, POLH, GSTπ and γ-GT1. A recent study found that Twist can directly combine ABCC4 and ABCC5 promoters and increase their expression levels in breast epithelial cells (37). However, in our study, we did not find this phenomenon, which may be due to the different cell lines. P-gp, a transmembrane glycoprotein encoded by the ABCB1 gene, is the first and most important human ABC transporter and confer a multidrug-resistance phenotype to cancer cells (20). Clinically, P-gp is involved in the process of local metastatic dissemination and drug resistance of colorectal carcinoma cells (38). We further confirmed that high expression of Twist increased P-gp expression in CRC cells. Importantly, we found clinical correlation of Twist and P-gp expression in human CRC specimens. Software analysis showed that the promoter of ABCB1 have Twist binding sites (CANNTG). It is worth further investigation to assess whether Twist can directly combine the promoter of ABCB1 and promote P-gp expression.

In summary, our studies have demonstrated that Twist expression in human CRC cells can mediate EMT and the development of the CSC phenotype as well as chemoresistance. Therapeutic targeting of Twist may be a novel method to enhance the efficacy of chemotherapy and improve outcomes for patients with metastatic CRC.

Acknowledgements

This work was funded by the Natural Science Foundation of Hubei Province (no. 2015CFB206).

References

1 

Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Wu Y and Zhou BP: Snail: More than EMT. Cell Adh Migr. 4:199–203. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Christofori G: New signals from the invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Barrallo-Gimeno A and Nieto MA: The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 132:3151–3161. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Wang H, Wang HS, Zhou BH, Li CL, Zhang F, Wang XF, Zhang G, Bu XZ, Cai SH and Du J: Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLoS One. 8:e566642013. View Article : Google Scholar

7 

Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Nuti SV, Mor G, Li P and Yin G: TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis. Oncotarget. 5:7260–7271. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Wushou A, Hou J, Zhao YJ and Shao ZM: Twist-1 up-regulation in carcinoma correlates to poor survival. Int J Mol Sci. 15:21621–21630. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, et al: Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 65:5153–5162. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan XY, Chua CW, Leung SC, Na Y and Wang X: Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol. 38:598–606. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Kong D, Li Y, Wang Z and Sarkar FH: Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel). 3:716–729. 2011. View Article : Google Scholar

15 

Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S and Sarkar FH: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI

16 

Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, Wang HS, Cai SH and Du J: Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol. 723:156–166. 2014. View Article : Google Scholar

17 

Kim YH, Kim G, Kwon CI, Kim JW, Park PW and Hahm KB: TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β 1. Oncol Rep. 31:1380–1388. 2014.PubMed/NCBI

18 

Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI

19 

He H, Ni J and Huang J: Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett. 7:1352–1362. 2014.PubMed/NCBI

20 

Xue X and Liang XJ: Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer. 31:100–109. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Logullo AF, Nonogaki S, Pasini FS, Osório CA, Soares FA and Brentani MM: Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: Association with progression. Oncol Rep. 23:313–320. 2010.PubMed/NCBI

22 

Xue CS, Plieth D, Venkov C, Xu C and Neilson EG: The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 63:3386–3394. 2003.PubMed/NCBI

23 

Sheehan KM, Gulmann C, Eichler GS, Weinstein JN, Barrett HL, Kay EW, Conroy RM, Liotta LA and Petricoin EF III: Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene. 27:323–331. 2008. View Article : Google Scholar

24 

Jung HY and Yang J: Unraveling the TWIST between EMT and cancer stemness. Cell Stem Cell. 16:1–2. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Galván JA, Helbling M, Koelzer VH, Tschan MP, Berger MD, Hädrich M, Schnüriger B, Karamitopoulou E, Dawson H, Inderbitzin D, et al: TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget. 6:874–885. 2015. View Article : Google Scholar :

26 

Fan YL, Zheng M, Tang YL and Liang XH: A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett. 6:1174–1180. 2013.PubMed/NCBI

27 

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI

28 

McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL and Ford HL: Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest. 119:2663–2677. 2009. View Article : Google Scholar : PubMed/NCBI

29 

Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI

31 

Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828. 2009. View Article : Google Scholar : PubMed/NCBI

32 

Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD and Wang LH: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI

33 

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 31:277–283. 2007.PubMed/NCBI

34 

Fukuda Y and Schuetz JD: ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 83:1073–1083. 2012. View Article : Google Scholar : PubMed/NCBI

35 

Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY, et al: Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI

37 

Saxena M, Stephens MA, Pathak H and Rangarajan A: Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporterss. Cell Death Dis. 2:e1792011. View Article : Google Scholar

38 

Zorzos HS, Lazaris AC, Korkolopoulou PA, Kavantzas NG, Tseleni-Balafouta S, Patsouris ES, Tsavaris NV and Davaris PS: Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential. Pathology. 35:315–318. 2003. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2016
Volume 48 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Deng, J., Zhang, W., Xu, X., Zhang, F., Tao, W., Ye, J., & Ge, W. (2016). Twist mediates an aggressive phenotype in human colorectal cancer cells. International Journal of Oncology, 48, 1117-1124. https://doi.org/10.3892/ijo.2016.3342
MLA
Deng, J., Zhang, W., Xu, X., Zhang, F., Tao, W., Ye, J., Ge, W."Twist mediates an aggressive phenotype in human colorectal cancer cells". International Journal of Oncology 48.3 (2016): 1117-1124.
Chicago
Deng, J., Zhang, W., Xu, X., Zhang, F., Tao, W., Ye, J., Ge, W."Twist mediates an aggressive phenotype in human colorectal cancer cells". International Journal of Oncology 48, no. 3 (2016): 1117-1124. https://doi.org/10.3892/ijo.2016.3342